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Background. Single agent prophylaxis with ﬂuoroquinolones (FQ) or cephalospo-
rins (drugs of choice) or trimethoprim-sulfamethoxazole or aminoglycosides
(alternatives) is recommended prior to transrectal ultrasound guided prostate biopsy
(TRUS-biopsy). However increasing FQ resistance (FQ-R) has led to a rise in post-
biopsy infections. We sought to compare the rate of infectious related complications
in patients receiving ciproﬂoxacin vs alternative regimens such as ciproﬂoxacin plus a
cephalosporin or a non-FQ regimen for TRUS-biopsy prophylaxis.
Methods. A total of 487 men who underwent a TRUS-biopsy at VA Boston
Healthcare System between 2011-2013 were retrospectively evaluated for infections
within 30 days, including symptomatic urinary tract infection (UTI) with fever, bacter-
emia, or sepsis. Men undergoing concurrent procedures or lacking documentation of
prophylaxis compliance were excluded. Electronic records were used to extract out-
come data from the national VA healthcare system, including outpatient and urgent
care visits.
Results. Of 455 men evaluated, there were 25 infections (5.5%), with sepsis occur-
ring in 2.4%, UTI in 1.5% and bacteremia in 0.4% of patients. E. coli was the most com-
mon urine (89%) and blood pathogen (92%), with FQ-R rates of 88% and 91%
respectively. Ciproﬂoxacin alone was associated with signiﬁcantly more infections
than ciproﬂoxacin plus an additional agent (p = 0.019). Intramuscular gentamicin
alone was also signiﬁcantly associated with a higher infection rate compared to all
other regimens (p = 0.014). Ciproﬂoxacin plus cefpodoxime was the most common
combination regimen. Any combination was highly protective, with a 75% reduction
in infection rate compared to ciproﬂoxacin or gentamicin alone (OR 0.25, 95% CI 0.06;
0.77, p = 0.01). Diabetes, immunosuppression, hospitalization within prior year, and
UTI within the previous 6 months were not associated with post-biopsy infection risk.
Conclusion. The overall incidence of post TRUS-biopsy infection in this cohort
was higher than previous reports. The ﬁndings suggest that ciproﬂoxacin or gentami-
cin alone are inferior regimens compared to a combination regimen. The preferred
combination likely depends on local susceptibility data.
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